Ben J. Koszegi

Fitzroy, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Response to methodological concerns in cumulative isotretinoin dose trials.

Response to methodological concerns in cumulative isotretinoin dose trials.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 06, 2026

Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial.

Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 30, 2026

Colchicine as a treatment option for inherited epidermolysis bullosa.

Colchicine as a treatment option for inherited epidermolysis bullosa.

Journal: Clinical and experimental dermatology

Published: October 27, 2024

The development and validation of an investigator global assessment score for keratosis pilaris.

The development and validation of an investigator global assessment score for keratosis pilaris.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 18, 2024

Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy.

Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 02, 2023

Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions.

Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 24, 2023

Dapsone for the management of severe epidermolysis bullosa simplex: A case report and evidence for a repurposing trial.

Dapsone for the management of severe epidermolysis bullosa simplex: A case report and evidence for a repurposing trial.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 25, 2023

Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience.

Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience.

Journal: Clinical and experimental dermatology

Published: June 23, 2023

Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.

Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.

Journal: Frontiers in medicine

Published: January 22, 2023

Showing 1-9 of 9

Last Updated: 09/26/2026